Form 4: AYTU Director Liu Receives 10,000 Restricted Shares

AYTU BioPharma Director Vivian H. Liu was granted 10,000 shares of restricted common stock, vesting on October 3, 2026.

Summary

• Vivian H. Liu, a Director of AYTU BioPharma, Inc., acquired 10,000 shares of common stock.
• This acquisition was a grant of restricted stock with a transaction price of $0 per share.
• The restricted stock is scheduled to vest on October 3, 2026.
• Following this transaction, Ms. Liu beneficially owns 19,825 shares of AYTU common stock.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged trading plan.
• A Limited Power of Attorney was granted by Vivian Liu on September 17, 2025, to several individuals to execute and file Forms 3, 4, and 5 on her behalf.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive signal, aligning management interests with shareholders. While not a direct cash investment, it indicates continued commitment and confidence. The routine nature of the Form 4 and the Power of Attorney prevents a higher score, as it doesn't reveal new operational or financial performance.

Positives

• The grant of restricted stock aligns the director's interests with those of shareholders, promoting long-term commitment to the company's performance.
• The increase in beneficial ownership by a director signals continued confidence in the company's future prospects.

Negatives

• The shares are restricted and do not vest until October 3, 2026, meaning they are not immediately liquid or fully owned by the director.
• The transaction price of $0 indicates a grant, not a direct cash purchase, so there is no immediate cash investment by the director in this specific transaction.

Risks

• The Power of Attorney includes an indemnification clause where Vivian Liu agrees to indemnify AYTU and the attorneys-in-fact against losses, claims, damages, or liabilities arising from untrue statements or omissions in information provided for SEC filings.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting date of the restricted stock.

Management Comments

• "The undersigned hereby constitutes and appoints Jake Siciliano, Ryan Selhorn, Luke Schafer, Fei Gao and Joshua Disbrow, each acting alone, as the undersigneds true and lawful attorney-in-fact to execute for and on behalf of the undersigned, in the undersigneds capacity as a director or officer of AYTU BioPharma, Inc., Forms 3, 4 and 5."
• "The undersigned acknowledges that neither AYTU nor the foregoing attorney-in-fact... are not assuming any liability for the undersigneds responsibility to comply with the requirements of Section 13 or Section 16 or the Exchange Act or Rule 144..."

Industry Context

This filing is a standard insider transaction disclosure and does not provide broader industry context. It reflects a common practice of compensating directors with equity to align their interests with shareholders, particularly in the biotechnology sector where long-term value creation is key.

Comparison to Industry Standards

• The grant of restricted stock to a director is a common form of equity compensation in the biotechnology and pharmaceutical industry, aligning director incentives with long-term company performance.
• The specific amount of 10,000 shares and the vesting schedule are typical for such grants, though the value would depend on AYTU's stock price at the time of vesting. Without specific peer company compensation data, a direct comparison of the grant size to comparable companies like BioNTech or Moderna's director compensation is not feasible from this filing alone.

Corporate Governance

Related Party Transactions

• The grant of 10,000 restricted shares to Vivian H. Liu, a director of AYTU BioPharma, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• **Shareholders**: The equity grant aligns the director's long-term interests with shareholders, potentially fostering better governance and strategic decisions aimed at increasing shareholder value.
• **Management/Directors**: The grant serves as a form of compensation and incentive for the director's continued service and performance, reinforcing their commitment to the company.

Next Steps

• The restricted stock is scheduled to vest on October 3, 2026.
• Vivian H. Liu will continue to file Forms 3, 4, and 5 as required by Section 16(a) of the Exchange Act, with the assistance of the appointed attorneys-in-fact.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice aimed at aligning interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, based solely on this filing, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

AYTU BioPharma, Vivian Liu, Form 4, Restricted Stock, Director Compensation, Equity Grant, Insider Ownership, AYTU